Sales/sh Y/Y
Revenue growth per diluted share, trailing twelve months against the prior twelve
How it is worked out
Revenue per diluted share, trailing twelve months against the prior twelveDiluted shares counts every share that could come to exist, including options and convertibles. Measuring per share means growth paid for by issuing shares does not count as growth in an owner's claim on the business.
How to read it
0% earns a 1, 80% a 10, logarithmically
Highest on this measure
| # | Company | Sales/sh Y/Y |
|---|---|---|
| 1 | VIR Vir Biotechnology, Inc. | 1,469.72% |
| 2 | IPSC Century Therapeutics, Inc. | 1,405.08% |
| 3 | ASTS AST SPACEMOBILE, INC. | 1,322.04% |
| 4 | ABUS ARBUTUS BIOPHARMA CORP | 1,041.89% |
| 5 | GUBRA.CO Gubra A/S | 900.02% |
| 6 | NUVB Nuvation Bio Inc. | 831.24% |
| 7 | MGTX MeiraGTx Holdings plc | 809.99% |
| 8 | PTGX Protagonist Therapeutics, Inc | 715.64% |
Which figures it needs
Computed from 2 figures taken from the filing:
revenuediluted_shares
The XBRL tags behind it
These are the element names looked for in a filing, in order. The first one a company reports is the one used, and the company page names which it was — so any figure here can be checked against the filing it came from.
RevenueFromContractWithCustomerExcludingAssessedTaxRevenuesRevenueFromContractWithCustomerIncludingAssessedTaxSalesRevenueNetSalesRevenueServicesNetRevenueFromContractsWithCustomersRevenueWeightedAverageNumberOfDilutedSharesOutstandingWeightedAverageNumberOfSharesOutstandingDilutedWeightedAverageNumberOfDilutedSharesOutstandingDilutedAdjustedWeightedAverageSharesWeightedAverageSharesWeightedAverageNumberOfSharesOutstandingBasicWeightedAverageNumberOfSharesOutstandingNumberOfSharesOutstandingSharesDerivedFromEarningsPerShare
Whether it counts
This measure is counted in Growth by default. It can be taken out on the dashboard, and the dimension is then measured over whatever is left.